Bonus BioGroup Enters Into an Exclusive Agreement for the Use of Engineered Nanoparticle Technology to Enhance Bone Regeneration
Bonus BioGroup to Hold Pre-IND Meeting with FDA Focused on Proposed Clinical Trial in the US
Bonus BioGroup Raises Investment of 5.2 Million NIS through Private Offering at 60 Cents per Share
Bonus BioGroup Announces Chief Scientist Support of R&D Program Totalling 6.4 Million NIS
Bonus BioGroup Receives EU Grant for Joint Development of New Method for Graft Tracking In Vivo
Bonus BioGroup Announces Agreement to Develop Innovative Biological Components
The agreement allows Bonus to receive FDA approval for innovative biological components which will be integrated into its manufactured transplants. These will be submitted to the FDA at no cost for Bonus.
Bonus Therapeutics Selected Amongst 100 Most Promising Innovative Technology Companies in Europe
Bonus BioGroup Announces Completion of Recruitment of 20 Patients for Clinical Trial to Repair Human Facial Bone Deficiency
Bonus BioGroup Announces Receipt of European GMP and International ISO-9001 Certification